A Landmark Year for Atra Zist Aray: From Product Innovation to the “Daatra” IPO
Atra Zist Aray successfully concluded the year 2025 with remarkable achievements, including active participation in scientific and industrial events, the launch of innovative products, expansion of export programs, and the initial public offering (IPO) of its shares on the Tehran Stock Exchange. These milestones marked one of the most dynamic and impactful years in the company’s history.
According to the Public Relations Office of Atra Zist Aray, the publicly traded biotechnology company operates under the stock symbol “Daatra.” The company specializes in the production of biocosmeceutical products with therapeutic and aesthetic applications, developed based on advanced biotechnology and pharmaceutical sciences.
Atra Zist Aray began its operations in 2014 under the name “Imen Vaccine Alborz” in the Alborz Industrial Town in Iran. As the company expanded its activities in biotechnology-based cosmetic and therapeutic products, it later rebranded to Atra Zist Aray.
Strong Industry Presence and Continued Production
Throughout 2025, the company maintained consistent production while strengthening its presence at major scientific conferences, exhibitions, and specialized medical congresses. During the same period, Atra Zist Aray achieved several key milestones in product development, export expansion, and capital market activities.
One notable aspect of the company’s performance was the continuous operation of its manufacturing facility during the 12‑day conflict period, without any production shutdown or disruption in raw material supply. This demonstrated the resilience and operational stability of the company.
Annual General Meeting and Shareholder Decisions
The company’s Annual General Meeting (AGM) for the fiscal year ending March 20, 2025, was held on August 5, 2025, with more than 74% shareholder participation. This meeting was particularly significant as it was the first AGM after Atra Zist Aray’s listing on the Tehran Stock Exchange in 2024.
During the meeting, the company’s financial statements and the board of directors’ report were approved, and shareholders agreed to distribute 94 rials dividend per share.
Export Expansion and Technology Transfer
In the summer of 2025, Atra Zist Aray announced plans to export its products to 20 countries. The company also revealed the technology transfer of its “Dyston” product to two partner companies in Turkey and Poland, a strategic step that is expected to accelerate the company’s international growth.
Showcasing Dyston at Medical Congresses
Atra Zist Aray participated in the exhibition held alongside three major gastroenterology and liver disease conferences in Tehran from September 9 to September 12. These events included:
- The 3rd Comprehensive Advanced Endoscopy Congress
- The 11th Tehran Hepatitis Congress
- The 4th Gastroenterology and Liver Congress
During these events, the company introduced “Dyston” (Botulinum Toxin Type A) to medical specialists and subspecialists. This product has gained attention not only for aesthetic applications but also for therapeutic treatments and weight management research.
Participation in Pharmaceutical and Dermatology Events
From August 27 to August 29, Atra Zist Aray actively participated in the 47th National Iranian Pharmacists Day Congress. Shortly afterward, the company showcased its latest achievements at the Khorasan Dermatology Congress, held in Mashhad from September 10 to September 12.
Iran Pharma Exhibition and Launch of Fleurvisage
Continuing its active industry engagement, Atra Zist Aray participated in the 10th Iran Pharma International Exhibition from September 24 to September 26, where the company presented its latest innovations.
During the exhibition’s press conference, the company announced the launch of “Fleurvisage,” a dermatological serum designed to reduce white spots caused by vitiligo. With continuous use over several months, the product helps restore skin pigmentation and significantly reduce visible vitiligo patches.
Participation in the Shiraz International Dermatology Congress
The company’s scientific engagement continued in November when Atra Zist Aray participated in the 3rd Shiraz International Dermatology Congress, held from November 12 to November 14. This congress is recognized as one of the most important scientific gatherings in Iran’s dermatology field.
Investor Presentation and Market Entry
One of the most significant milestones of 2025 for the company was the IPO introduction session for its shares under the symbol “Daatra”, held on November 3 at the Tehran Stock Exchange Conference Center. The event was attended by capital market professionals, investors, offering advisors, and representatives of the Securities and Exchange Organization.
During this session, the company also announced that a study conducted at Ankara University in Turkey confirmed that Dyston demonstrates quality and efficacy comparable to well‑known global Botulinum Toxin Type A brands.
Regulatory Approval for Luxafill Hailow
In the same month, Iran’s Food and Drug Administration (FDA) approved the registration and production license for the company’s injectable mesogel product “Luxafill Hailow.”
This product is supplied as a 1‑ml prefilled syringe and is designed for skin rejuvenation and aesthetic dermatology treatments.
Successful IPO of Daatra Shares
On November 19, Atra Zist Aray successfully offered 9% of its shares to the public on the Tehran Stock Exchange. The final discovery price was 3,796 rials per share, and more than one million investors participated in purchasing the “Daatra” shares.
The company announced that the funds raised from the IPO will be allocated to:
- expanding company operations
- launching a raw material production line
- strengthening export programs
- introducing new biotechnology products
Continued Presence in Cosmetic and Medical Exhibitions
Atra Zist Aray continued its industry engagement by participating in the 7th Iran Cosmetica Exhibition from December 10 to December 12, focused on cosmetics, hygiene products, detergents, and related industries.
The company also attended the 25th Gastroenterology and Liver Congress, held from December 16 to December 19.
Introduction Ceremony for Luxafill Hailow
In February, the company held an official ceremony to introduce Luxafill Hailow as its newest product. The event was attended by prominent professors and medical specialists.
Luxafill Hailow belongs to the category of biocompatible injectable hydrogels, a rapidly growing segment in the skin rejuvenation and aesthetic medicine market.
A Strategic and Transformative Year
Reviewing Atra Zist Aray’s performance in 2025 reveals a year defined by product innovation, export expansion, scientific engagement, and entry into the capital market.
With these achievements, the company has positioned itself for accelerated growth in the biotechnology and aesthetic medicine industries, making 2025 a transformative year that could shape its trajectory for years to come.
بدون دیدگاه